MDS Inc. Repositions Executive Management Team - Creates Chief Operating Officer Position
06 Maggio 2004 - 3:00PM
PR Newswire (US)
MDS Inc. Repositions Executive Management Team - Creates Chief
Operating Officer Position TORONTO, May 6 /PRNewswire-FirstCall/ --
MDS Inc. (TSX: MDS, NYSE: MDZ) today announced the creation of a
new executive management position - Chief Operating Officer. This
position reflects our commitment to strengthening and focusing our
resources at every level of the organization. An executive search
firm has been retained to assist in filling this important role.
John Rogers, President and CEO of MDS Inc. said, "This decision
further underscores our commitment to positioning the company and
the senior team of MDS for future growth. The creation of the COO
position is an integral part of aligning the organization to
deliver enhanced performance," he added. Over the last several
quarters, there have been a number of changes and additions to the
MDS Board of Directors and the Executive Management Team. This
includes the board appointment of John Mayberry (Lead Director) and
the management appointments of Jim Garner, Executive Vice-President
and CFO and David Poirier, President, Enterprise Services and CIO.
The company also announced the resignation of Ian Lennox, Group
President and CEO, Pharmaceutical and Biotech Markets. Ian will be
leaving the company at the end of May to pursue other interests. In
commenting on Ian Lennox's resignation John Rogers said, "Ian
joined us in 2000 with the acquisition of Phoenix. While at MDS he
made a number of significant contributions, in particular, he led
the integration of Phoenix into MDS Pharma Services and provided
leadership to the analytical instruments and proteomics
businesses." Ian Lennox commented, "MDS is one of Canada's leading
health and life sciences companies. It has a bright future as a
global provider of products and services to pharma and biotech
customers around the world. It was a pleasure to be a part of
building MDS Pharma Services and MDS Sciex which combined represent
almost $800 million in annualized revenues." At MDS Inc., our more
than 10,000 highly skilled people provide enabling products and
services for the development of drugs and the diagnosis and
management of disease. We focus on helping to discover new drugs,
assisting doctors to diagnose and treat patients and preventing the
spread of disease. Find out more about MDS Inc. at
http://www.mdsintl.com/ or by calling 1-888-MDS-7222, 24 hours a
day. DATASOURCE: MDS Inc. CONTACT: Investor Relations: Sharon
Mathers, (416) 675-6777 ext. 2695; Media Relations: Naomi Nemeth,
(416) 213-4692
Copyright